Get the Stockscreener App
9.38
3.20%
-0.31
After Hours:
9.59
0.21
+2.24%
Oric Pharmaceuticals Inc stock is traded at $9.38, with a volume of 995.76K.
It is down -3.20% in the last 24 hours and down -24.84% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$9.69
Open:
$9.68
24h Volume:
995.76K
Relative Volume:
0.73
Market Cap:
$913.51M
Revenue:
-
Net Income/Loss:
$-137.25M
P/E Ratio:
-4.963
EPS:
-1.89
Net Cash Flow:
$-121.97M
1W Performance:
-14.73%
1M Performance:
-24.84%
6M Performance:
-3.00%
1Y Performance:
+11.27%
1-Day Range:
$9.33
$9.74
1-Week Range:
$9.33
$12.50
52-Week Range:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.38 | 943.70M | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Evercore ISI | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Responsive Playbooks and the ORIC Inflection - news.stocktradersdaily.com
Stempoint Capital LP Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Vivo Capital LLC Has $31.74 Million Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Resolute Capital Asset Partners LLC Invests $2.31 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Analyst Rating Update from Wells Fargo | ORIC Stock News - GuruFocus
Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Wedbush Reiterates 'Outperform' Rating for ORIC Pharmaceuticals | ORIC Stock News - GuruFocus
Wells Fargo raises ORIC Pharmaceuticals stock price target on promising cancer drug data - Investing.com Canada
Oric Pharmaceuticals, Inc. Presents Enozertinib Program Update - TradingView
JPMorgan Chase & Co. Raises Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals (ORIC) Showcases Promising Phase 1b Trial D - GuruFocus
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 - Sahm
Fund Flows: Will ORIC Pharmaceuticals Inc stock see PE expansionPortfolio Growth Summary & Growth Focused Investment Plans - moha.gov.vn
ORIC Pharmaceuticals (Nasdaq: ORIC) shares Phase 1b NSCLC data with 67% ORR - Stock Titan
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust ... - Bakersfield.com
Dir Kunkel Acquires 5,534 Of Oric Pharmaceuticals Inc [ORIC] - TradingView
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oric Pharmaceuticals (ORIC) Reveals Promising Trial Results for Enozertinib - GuruFocus
Oric Pharmaceuticals (ORIC) Presents Promising Phase 1b Trial Re - GuruFocus
Is ORIC Pharmaceuticals Inc. (4TZ) stock attractive for growth funds2025 Trade Ideas & Daily Profit Focused Stock Screening - Newser
ORIC (Nasdaq: ORIC) shows 35% ORR, 100% DCR in Phase 1b HER2 NSCLC trial - Stock Titan
ORIC Pharmaceuticals, Inc. Announces Data from a Phase 1b Trial of Enozertinib (ORIC-114) at the ESMO Asia Congress 2025 - marketscreener.com
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 - The Manila Times
ORIC Pharmaceuticals Reports Promising Preliminary Data for Enozertinib in 1L EGFR PACC Patients with High Response Rates and Favorable Safety Profile - Quiver Quantitative
ORIC Pharmaceuticals (NASDAQ: ORIC) sees 80% ORR, 100% CNS ORR in 1L EGFR PACC NSCLC - Stock Titan
What analysts say about ORIC Pharmaceuticals Inc stockBearish Engulfing Patterns & High Yield Trading Plans - earlytimes.in
Will ORIC Pharmaceuticals Inc. stock see PE expansionProduct Launch & Technical Buy Zone Confirmation - Newser
Why ORIC Pharmaceuticals Inc. (4TZ) stock attracts HNW investorsIPO Watch & Risk Controlled Swing Alerts - Newser
Can ORIC Pharmaceuticals Inc. stock reach $100 price targetQuarterly Trade Review & High Win Rate Trade Tips - Newser
Why analysts recommend ORIC Pharmaceuticals Inc. (4TZ) stockMarket Trend Review & Precise Buy Zone Tips - Newser
Geode Capital Management LLC Trims Stock Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals Announces Late-Breaking Oral Presentations on Enozertinib (ORIC-114) at ESMO Asia Congress 2025 - Quiver Quantitative
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - The Manila Times
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 5.6%Here's Why - MarketBeat
ORIC Pharmaceuticals (ORIC) Stock Analysis Report | Financials & Insights - Benzinga
Top 3 Health Care Stocks That May Rocket Higher In December - Benzinga
Can ORIC Pharmaceuticals Inc. stock deliver sustainable ROEJuly 2025 Review & Consistent Income Trade Ideas - Newser
Why ORIC Pharmaceuticals Inc. stock could rally in 2025Take Profit & Daily Growth Stock Investment Tips - Newser
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Is ORIC Pharmaceuticals Inc. (4TZ) stock positioned for secular growth2025 Technical Overview & Stepwise Trade Signal Implementation - Newser
Why ORIC Pharmaceuticals Inc. (4TZ) stock benefits from AI revolutionRate Hike & AI Driven Stock Reports - Newser
ORIC Pharmaceuticals (ORIC) Valuation Check as New Phase 1b Enozertinib Lung Cancer Data Approaches - Yahoo Finance
What MACD trends signal for ORIC Pharmaceuticals Inc. (4TZ) stock2025 Performance Recap & Detailed Earnings Play Strategies - Newser
How buyback programs support ORIC Pharmaceuticals Inc. (4TZ) stock2025 Key Lessons & AI Driven Stock Price Forecasts - Newser
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 - The Manila Times
ORIC Pharmaceuticals (Nasdaq: ORIC) to share Phase 1b HER2 exon 20 NSCLC data at ESMO Asia 2025 - Stock Titan
Bull Bear: How strong is ORIC Pharmaceuticals Inc. stock revenue growthJuly 2025 Sector Moves & Safe Capital Growth Tips - BỘ NỘI VỤ
Franklin Resources Inc. Raises Position in Oric Pharmaceuticals, Inc. $ORIC - Defense World
How strong is ORIC Pharmaceuticals Inc. stock revenue growthJuly 2025 Selloffs & Capital Protection Trade Alerts - BỘ NỘI VỤ
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):